Analysts Set Kura Oncology, Inc. (NASDAQ:KURA) Price Target at $27.38

Kura Oncology, Inc. (NASDAQ:KURA) has earned a consensus recommendation of “Moderate Buy” from the eleven research firms that are presently covering the company, Marketbeat.com reports. Two analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $27.38.

KURA has been the subject of a number of research reports. Bank of America decreased their price objective on shares of Kura Oncology from $36.00 to $29.00 and set a “buy” rating for the company in a report on Friday, November 22nd. Scotiabank decreased their price target on shares of Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating for the company in a report on Wednesday, January 8th. HC Wainwright raised their target price on shares of Kura Oncology from $32.00 to $37.00 and gave the stock a “buy” rating in a report on Thursday, November 21st. UBS Group assumed coverage on Kura Oncology in a research report on Thursday, October 24th. They set a “buy” rating and a $27.00 price target on the stock. Finally, Stifel Nicolaus lowered Kura Oncology from a “buy” rating to a “hold” rating and reduced their price objective for the company from $26.00 to $19.00 in a research report on Monday, October 14th.

Insider Activity

In related news, insider Mollie Leoni sold 4,963 shares of the stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $39,058.81. Following the completion of the transaction, the insider now owns 88,253 shares in the company, valued at $694,551.11. This represents a 5.32 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP Thomas James Doyle sold 4,949 shares of the business’s stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $38,948.63. Following the sale, the senior vice president now owns 88,193 shares in the company, valued at $694,078.91. This trade represents a 5.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 12,255 shares of company stock valued at $100,739. Company insiders own 5.50% of the company’s stock.

Hedge Funds Weigh In On Kura Oncology

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Harbor Capital Advisors Inc. lifted its holdings in shares of Kura Oncology by 4.4% in the fourth quarter. Harbor Capital Advisors Inc. now owns 49,371 shares of the company’s stock valued at $430,000 after buying an additional 2,076 shares during the period. JPMorgan Chase & Co. lifted its holdings in Kura Oncology by 0.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 409,241 shares of the company’s stock valued at $7,997,000 after acquiring an additional 3,092 shares during the last quarter. Armistice Capital LLC boosted its position in shares of Kura Oncology by 14.7% during the 2nd quarter. Armistice Capital LLC now owns 2,350,000 shares of the company’s stock valued at $48,386,000 after purchasing an additional 302,000 shares in the last quarter. Alethea Capital Management LLC boosted its position in shares of Kura Oncology by 2.4% during the 2nd quarter. Alethea Capital Management LLC now owns 265,906 shares of the company’s stock valued at $5,475,000 after purchasing an additional 6,300 shares in the last quarter. Finally, AQR Capital Management LLC grew its stake in shares of Kura Oncology by 251.5% in the 2nd quarter. AQR Capital Management LLC now owns 81,655 shares of the company’s stock worth $1,681,000 after purchasing an additional 58,422 shares during the last quarter.

Kura Oncology Price Performance

KURA opened at $7.77 on Friday. The company has a market capitalization of $604.20 million, a P/E ratio of -3.29 and a beta of 0.81. The company has a 50-day moving average of $9.23 and a 200-day moving average of $15.69. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47. Kura Oncology has a 1-year low of $6.98 and a 1-year high of $24.17.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.63) earnings per share for the quarter, beating the consensus estimate of ($0.64) by $0.01. During the same period in the prior year, the business earned ($0.50) earnings per share. Equities analysts expect that Kura Oncology will post -2.44 EPS for the current fiscal year.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.